Meeley M P, Ernsberger P, McCauley P M, Reis D J
Division of Neurobiology, Cornell University Medical College, New York, NY 10021.
J Hypertens Suppl. 1988 Dec;6(4):S490-3.
Polyclonal antisera raised against para-aminoclonidine coupled to haemocyanin exhibit high affinity for para-aminoclonidine, clonidine and chloroethylclonidine (IC50 less than 100 nmol/l). Anti-para-aminoclonidine antibodies also cross-react with naphazoline, oxymetazoline and tolazoline at moderate concentrations (IC50, 300-500 mumol/l); the phenyl-imidazoles detomidine, medetomidine and MPV830 are weakly cross-reactive (IC50 greater than 0.2 mmol/l). All of these compounds bind with high affinity to both imidazole and alpha 2-adrenergic receptors. Compounds which are imidazole- or alpha 2-specific do not cross-react with anti-para-aminoclonidine antibodies (IC50 greater than 1 mmol/l). Anti-para-aminoclonidine also recognizes an endogenous clonidine-displacing substance in the brain. Thus, (a) binding to anti-para-aminoclonidine antibodies defines a subset of phenyl-imidazol(in)e ligands which bind to both imidazole and alpha 2-adrenergic receptors, suggesting that anti-para-aminoclonidine recognition sites resemble a hybrid of the two receptor types; (b) antibodies to imidazole- or alpha 2-specific agents may be useful as models for differentiating between these types; (c) since clonidine-displacing substance is recognized by anti-para-aminoclonidine antibodies, it may have phenyl and imidazole rings as parts of its chemical structure.
用与血蓝蛋白偶联的对氨基可乐定免疫动物所产生的多克隆抗血清,对氨基可乐定、可乐定和氯乙可乐定具有高亲和力(半数抑制浓度小于100纳摩尔/升)。抗对氨基可乐定抗体在中等浓度(半数抑制浓度为300 - 500微摩尔/升)时也与萘甲唑啉、羟甲唑啉和托拉唑啉发生交叉反应;苯基咪唑类药物右美托咪定、美托咪定和MPV830的交叉反应较弱(半数抑制浓度大于0.2毫摩尔/升)。所有这些化合物都与咪唑和α2 - 肾上腺素能受体具有高亲和力。咪唑特异性或α2特异性的化合物不与抗对氨基可乐定抗体发生交叉反应(半数抑制浓度大于1毫摩尔/升)。抗对氨基可乐定还能识别脑中一种内源性可乐定置换物质。因此,(a)与抗对氨基可乐定抗体结合定义了一类苯基咪唑(啉)配体的子集,它们与咪唑和α2 - 肾上腺素能受体都结合,这表明抗对氨基可乐定识别位点类似于这两种受体类型的混合体;(b)针对咪唑特异性或α2特异性药物的抗体可能作为区分这些类型的模型有用;(c)由于抗对氨基可乐定抗体能识别可乐定置换物质,它可能具有苯基和咪唑环作为其化学结构的一部分。